Suggested remit - To appraise the clinical and cost effectiveness of Pembrolizumab within its marketing authorisation for treating untreated, locally advanced or metastatic, triple negative breast cancer
Status In progress
Process STA 2018
ID number 1546

Provisional Schedule

Expected publication 21 April 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
28 November 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late- May 2020 when we will write to you about how you can get involved.
10 June 2019 - 08 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance